home / stock / crdf / crdf quote
Last: | $2.08 |
---|---|
Change Percent: | 0.0% |
Open: | $2.05 |
Close: | $2.08 |
High: | $2.1525 |
Low: | $2.03 |
Volume: | 728,089 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.08 | $2.05 | $2.08 | $2.1525 | $2.03 | 728,089 | 07-02-2024 |
$2.05 | $2.21 | $2.05 | $2.255 | $2.04 | 866,707 | 07-01-2024 |
$2.22 | $2.29 | $2.22 | $2.33 | $2.21 | 5,845,774 | 06-28-2024 |
$2.33 | $2.3 | $2.33 | $2.45 | $2.275 | 577,517 | 06-27-2024 |
$2.34 | $2.26 | $2.34 | $2.34 | $2.17 | 753,694 | 06-26-2024 |
$2.26 | $2.36 | $2.26 | $2.375 | $2.26 | 494,643 | 06-25-2024 |
$2.36 | $2.43 | $2.36 | $2.51 | $2.345 | 466,332 | 06-24-2024 |
$2.45 | $2.46 | $2.45 | $2.5 | $2.33 | 486,199 | 06-21-2024 |
$2.44 | $2.5 | $2.44 | $2.54 | $2.4 | 789,835 | 06-20-2024 |
$2.5 | $2.65 | $2.5 | $2.67 | $2.49 | 571,777 | 06-19-2024 |
$2.5 | $2.65 | $2.5 | $2.67 | $2.49 | 571,777 | 06-18-2024 |
$2.67 | $2.69 | $2.67 | $2.7751 | $2.53 | 944,711 | 06-17-2024 |
$2.7 | $2.8 | $2.7 | $2.82 | $2.59 | 567,420 | 06-14-2024 |
$2.83 | $2.95 | $2.83 | $3 | $2.71 | 405,417 | 06-13-2024 |
$2.95 | $3.01 | $2.95 | $3.09 | $2.92 | 241,542 | 06-12-2024 |
$2.95 | $2.95 | $2.95 | $3.02 | $2.88 | 264,267 | 06-11-2024 |
$2.95 | $2.92 | $2.95 | $3.07 | $2.86 | 567,027 | 06-10-2024 |
$2.93 | $2.94 | $2.93 | $3 | $2.75 | 745,918 | 06-07-2024 |
$2.98 | $2.96 | $2.98 | $3.05 | $2.86 | 512,324 | 06-06-2024 |
$2.98 | $3.03 | $2.98 | $3.05 | $2.93 | 518,315 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
Cardiff Oncology Inc. Website:
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...